(Q45356395)

13 December 2017

title

Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection (English)

1 reference

13 December 2017

1 reference

1 reference

D Moradpour

9

0 references

author name string

F Girardin

1

1 reference

13 December 2017

Y Daali

2

1 reference

13 December 2017

M Gex-Fabry

3

1 reference

13 December 2017

M Rebsamen

4

1 reference

13 December 2017

P Roux-Lombard

5

1 reference

13 December 2017

A Cerny

6

1 reference

13 December 2017

F Bihl

7

1 reference

13 December 2017

J Binek

8

1 reference

13 December 2017

F Negro

10

1 reference

13 December 2017

J Desmeules

11

1 reference

13 December 2017

Swiss Hepatitis C Cohort Study Group

12

1 reference

13 December 2017

publication date

26 January 2012

1 reference

Journal of Viral Hepatitis

13 December 2017

published in

1 reference

13 December 2017

volume

19

1 reference

13 December 2017

issue

8

1 reference

13 December 2017

page(s)

568-573

1 reference

Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, Greece

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

Crystal structure of human cytochrome P450 2D6

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01578.X

10.1111/J.1365-2893.2011.01578.X

21 January 2018

Identifiers

DOI

1 reference

13 December 2017

1 reference